Press Resease

Pharmacogenomics Market - Global Industry Analysis

Pharmacogenomics Market by Technology (Microarray, Polymerase Chain Reaction, Sequencing, Electrophoresis, Mass Spectrometry, and Others), Application (Infectious Diseases, Oncology, Neurological Diseases, Cardiovascular Diseases, Pain Management, Psychiatry, and Others), and End User (Research Institutions, Hospitals and Clinics, and Academic Institutes): Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 - 2025

Published Date: 27-Nov-2019 Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-5104 Status : Published

Global demand for pharmacogenomics market was valued at approximately USD 5,712.5 million in 2018, and is expected to generate revenue of around USD 10,492.2 million by end of 2025, growing at a CAGR of around 9.2% between 2019 and 2025.

Description

According to the report, global demand for pharmacogenomics market was valued at approximately USD 5,712.5 million in 2018, and is expected to generate revenue of around USD 10,492.2 million by end of 2025, growing at a CAGR of around 9.2% between 2019 and 2025.

The report covers forecast and analysis for the pharmacogenomics market on a global and regional level. The study provides historic data from 2016 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the pharmacogenomics market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the pharmacogenomics market on a global as well as regional level.

In order to give the users of this report a comprehensive view on the pharmacogenomics market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein Technology and services segment is benchmarked based on their market size, growth rate and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the pharmacogenomics market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new Technology launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the pharmacogenomics market on global and regional basis.

Pharmacogenomics is the combination of pharmacology and genomics. Pharmacogenomics studies the effect of genes on drug response. The aim of pharmacogenomics is to develop safe and effective doses and medication tailored to the genetic makeup of a person.

Factors such as increasing implementation of pharmacogenomics procedure, growing geriatric population, increasing adoption of personalized therapy, rapidly rising incidence of chronic disorders, and growing rate of adverse reactions will act as major driving factors in the growth of global pharmacogenomics market. Technological advancements in the field of pharmacogenomics and increasing awareness will act as an opportunity for the market players in the pharmacogenomics market. Nonetheless, high cost of diagnosis, lack of skilled professionals, and low awareness in developing regions will restrict the growth of global pharmacogenomics market.

The global pharmacogenomics market has been split into technology, application, end user, and region. Based on technology, pharmacogenomics market has been segmented into microarray, polymerase chain reaction, sequencing, electrophoresis, mass spectrometry, and others. The polymerase chain reaction segment accounted for the highest market share in 2018 due to irreplaceable nature. The application segment has been divided into infectious diseases, oncology, neurological diseases, cardiovascular diseases, pain management, psychiatry, and others. The end user segment has been divided into research institutions, hospitals and clinics, and academic institutes. The hospitals and clinics segment accounted for the highest market share in 2018 due to presence of latest molecular diagnostic infrastructure in hospitals.

North America will be the leading region during the forecast period. U.S. accounted for the highest share in the North America region due to growing execution of pharmacogenomics and quick implementation of latest healthcare technologies. Europe is likely to be the succeeding key market. The crucial reasons are existence of skilled healthcare professionals and increasing acceptance of personalized medicine. Asia Pacific will develop at the highest growth rate owing to presence of large patient group, rise in consciousness regarding pharmacogenomics, and high incidence of chronic diseases. Latin America region will propagate at a noteworthy rate through the assessment time. Middle East & Africa will show positive advancement in the projected time-frame.

The report also includes detailed profiles of key players such as Dynamic DNA Laboratories, Abbott Laboratories, Empire Genomics, LLC, Illumina, Inc., F. Hoffmann-La Roche Ltd., Myriad Genetics Inc., OneOme LLC, Thermo Fisher Scientific, Inc., and OPKO Health, Inc. among others.

This report segments the Global Pharmacogenomics Market as follows:

Global Pharmacogenomics Market: By Technology

  • Microarray
  • Polymerase Chain Reaction
  • Sequencing
  • Electrophoresis
  • Mass Spectrometry
  • Others

Global Pharmacogenomics Market: By Application

  • Infectious Diseases
  • Oncology
  • Neurological Diseases
  • Cardiovascular Diseases
  • Pain Management
  • Psychiatry
  • Others

Global Pharmacogenomics Market: By End User

  • Research Institutions
  • Hospitals and Clinics
  • Academic Institutes

Global Pharmacogenomics Market: By Region

  • North America
    • U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Pharmacogenomics, 2016-2025 (USD Million)
    • 2.2. Pharmacogenomics: Snapshot
  • Chapter 3. Pharmacogenomics - Industry Analysis
    • 3.1. Pharmacogenomics: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Increasing implementation of pharmacogenomics procedure
      • 3.2.2. Growing geriatric population
    • 3.3. Restraints
      • 3.3.1. High cost of diagnosis
      • 3.3.2. Lack of skilled professionals
    • 3.4. Opportunity
      • 3.4.1. Technological advancements in the field of pharmacogenomics
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis By Technology
      • 3.6.2. Market attractiveness analysis By Application
      • 3.6.3. Market attractiveness analysis By End User
      • 3.6.4. Market attractiveness analysis by Region
  • Chapter 4. Pharmacogenomics- Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Pharmacogenomics: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Technology launches
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Pharmacogenomics -Technology Analysis
    • 5.1. Global Pharmacogenomics overview: By Technology type
      • 5.1.1. Global Pharmacogenomics share, By Technology,2018 and 2025
    • 5.2. Microarray
      • 5.2.1. Global Pharmacogenomics by Microarray, 2016-2025 (USD Million)
    • 5.3. Polymerase Chain Reaction
      • 5.3.1. Global Pharmacogenomics by Polymerase Chain Reaction, 2016-2025 (USD Million)
    • 5.4. Sequencing
      • 5.4.1. Global Pharmacogenomics by Sequencing, 2016-2025 (USD Million)
    • 5.5. Electrophoresis
      • 5.5.1. Global Pharmacogenomics by Electrophoresis, 2016-2025 (USD Million)
    • 5.6. Mass Spectrometry
      • 5.6.1. Global Pharmacogenomics by Mass Spectrometry, 2016-2025 (USD Million)
    • 5.7. Others
      • 5.7.1. Global Pharmacogenomics by Others, 2016-2025 (USD Million)
  • Chapter 6. Global Pharmacogenomics -Application Analysis
    • 6.1. Global Pharmacogenomics overview: By Application
      • 6.1.1. Global Pharmacogenomics share, By Application, 2018 and 2025
    • 6.2. Infectious Diseases
      • 6.2.1. Global Pharmacogenomics By Infectious Diseases, 2016-2025 (USD Million)
    • 6.3. Oncology
      • 6.3.1. Global Pharmacogenomics By Oncology, 2016-2025 (USD Million)
    • 6.4. Neurological Diseases
      • 6.4.1. Global Pharmacogenomics By Neurological Diseases, 2016-2025 (USD Million)
    • 6.5. Cardiovascular Diseases
      • 6.5.1. Global Pharmacogenomics By Cardiovascular Diseases, 2016-2025 (USD Million)
    • 6.6. Infectious Disease
      • 6.6.1. Global Pharmacogenomics By Infectious Disease, 2016-2025 (USD Million)
    • 6.7. Pain Management
      • 6.7.1. Global Pharmacogenomics by Pain Management, 2016-2025 (USD Million)
    • 6.8. Psychiatry
      • 6.8.1. Global Pharmacogenomics by Psychiatry, 2016-2025 (USD Million)
    • 6.9. Others
      • 6.9.1. Global Pharmacogenomics by Others, 2016-2025 (USD Million)
  • Chapter 7. Global Pharmacogenomics -End User Analysis
    • 7.1. Global Pharmacogenomics overview: By End User
      • 7.1.1. Global Pharmacogenomics share, By End User, 2018 and 2025
    • 7.2. Research Institutions
      • 7.2.1. Global Pharmacogenomics by Research Institutions, 2016-2025 (USD Million)
    • 7.3. Hospitals and Clinics
      • 7.3.1. Global Pharmacogenomics by Hospitals and Clinics, 2016-2025 (USD Million)
    • 7.4. Academic Institutes
      • 7.4.1. Global Pharmacogenomics by Academic Institutes, 2016-2025 (USD Million)
  • Chapter 8. Global Pharmacogenomics - Regional Analysis
    • 8.1. Global Pharmacogenomics overview: by Region
      • 8.1.1. Global Pharmacogenomics share, by Region, 2018 and 2025
    • 8.2. North America
      • 8.2.1. North America Pharmacogenomics, 2016-2025 (USD Million)
      • 8.2.2. North America Pharmacogenomics revenue, By Technology,2016-2025 (USD Million)
      • 8.2.3. North America Pharmacogenomics revenue, By Application, 2016-2025 (USD Million)
      • 8.2.4. North America Pharmacogenomics revenue, By End User, 2016-2025 (USD Million)
      • 8.2.5. The U.S.
        • 8.2.5.1. The U.S. Pharmacogenomics revenue, By Technology,2016-2025 (USD Million)
        • 8.2.5.2. The U.S. Pharmacogenomics revenue, By Application, 2016-2025 (USD Million)
        • 8.2.5.3. The U.S. Pharmacogenomics revenue, By End User, 2016-2025 (USD Million)
      • 8.2.6. Rest of North America
        • 8.2.6.1. Rest of North America Pharmacogenomics revenue, By Technology,2016-2025 (USD Million)
        • 8.2.6.2. Rest of North America Pharmacogenomics revenue, By Application, 2016-2025 (USD Million)
        • 8.2.6.3. Rest of North America Pharmacogenomics revenue, By End User, 2016-2025 (USD Million)
    • 8.3. Europe
      • 8.3.1. Europe Pharmacogenomics, 2016-2025 (USD Million)
      • 8.3.2. Europe Pharmacogenomics revenue, By Technology,2016-2025 (USD Million)
      • 8.3.3. Europe Pharmacogenomics revenue, By Application, 2016-2025 (USD Million)
      • 8.3.4. Europe Pharmacogenomics revenue, By End User, 2016-2025 (USD Million)
      • 8.3.5. UK
        • 8.3.5.1. U.K. Pharmacogenomics revenue, By Technology,2016-2025 (USD Million)
        • 8.3.5.2. U.K. Pharmacogenomics revenue, By Application, 2016-2025 (USD Million)
        • 8.3.5.3. U.K. Pharmacogenomics revenue, By End User, 2016-2025 (USD Million)
      • 8.3.6. France
        • 8.3.6.1. France Pharmacogenomics revenue, By Technology,2016-2025 (USD Million)
        • 8.3.6.2. France Pharmacogenomics revenue, By Application, 2016-2025 (USD Million)
        • 8.3.6.3. France Pharmacogenomics revenue, By End User, 2016-2025 (USD Million)
      • 8.3.7. Germany
        • 8.3.7.1. Germany Pharmacogenomics revenue, By Technology,2016-2025 (USD Million)
        • 8.3.7.2. Germany Pharmacogenomics revenue, By Application, 2016-2025 (USD Million)
        • 8.3.7.3. Germany Pharmacogenomics revenue, By End User, 2016-2025 (USD Million)
      • 8.3.8. Rest of Europe
        • 8.3.8.1. Rest of Europe Pharmacogenomics revenue, By Technology,2016-2025 (USD Million)
        • 8.3.8.2. Rest of Europe Pharmacogenomics revenue, By Application, 2016-2025 (USD Million)
        • 8.3.8.3. Rest of Europe Pharmacogenomics revenue, By End User, 2016-2025 (USD Million)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Pharmacogenomics, 2016-2025 (USD Million)
      • 8.4.2. Asia Pacific Pharmacogenomics revenue, By Technology,2016-2025 (USD Million)
      • 8.4.3. Asia Pacific Pharmacogenomics revenue, By Application, 2016-2025 (USD Million)
      • 8.4.4. Asia Pacific Pharmacogenomics revenue, By End User, 2016-2025 (USD Million)
      • 8.4.5. China
        • 8.4.5.1. China Pharmacogenomics revenue, By Technology,2016-2025 (USD Million)
        • 8.4.5.2. China Pharmacogenomics revenue, By Application, 2016-2025 (USD Million)
        • 8.4.5.3. China Pharmacogenomics revenue, By End User, 2016-2025 (USD Million)
      • 8.4.6. Japan
        • 8.4.6.1. Japan Pharmacogenomics revenue, By Technology,2016-2025 (USD Million)
        • 8.4.6.2. Japan Pharmacogenomics revenue, By Application, 2016-2025 (USD Million)
        • 8.4.6.3. Japan Pharmacogenomics revenue, By End User, 2016-2025 (USD Million)
      • 8.4.7. India
        • 8.4.7.1. India Pharmacogenomics revenue, By Technology,2016-2025 (USD Million)
        • 8.4.7.2. India Pharmacogenomics revenue, By Application, 2016-2025 (USD Million)
        • 8.4.7.3. India Pharmacogenomics revenue, By End User, 2016-2025 (USD Million)
      • 8.4.8. Rest of Asia Pacific
        • 8.4.8.1. Rest of Asia Pacific Pharmacogenomics revenue, By Technology,2016-2025 (USD Million)
        • 8.4.8.2. Rest of Asia Pacific Pharmacogenomics revenue, By Application, 2016-2025 (USD Million)
        • 8.4.8.3. Rest of Asia Pacific Pharmacogenomics revenue, By End User, 2016-2025 (USD Million)
    • 8.5. Latin America
      • 8.5.1. Latin America Pharmacogenomics, 2016-2025 (USD Million)
      • 8.5.2. Latin America Pharmacogenomics revenue, By Technology,2016-2025 (USD Million)
      • 8.5.3. Latin America Pharmacogenomics revenue, By Application, 2016-2025 (USD Million)
      • 8.5.4. Latin America Pharmacogenomics revenue, By End User, 2016-2025 (USD Million)
      • 8.5.5. Brazil
        • 8.5.5.1. Brazil Pharmacogenomics revenue, By Technology,2016-2025 (USD Million)
        • 8.5.5.2. Brazil Pharmacogenomics revenue, By Application, 2016-2025 (USD Million)
        • 8.5.5.3. Brazil Pharmacogenomics revenue, By End User, 2016-2025 (USD Million)
      • 8.5.6. Rest of Latin America
        • 8.5.6.1. Rest of Latin America Pharmacogenomics revenue, By Technology,2016-2025 (USD Million)
        • 8.5.6.2. Rest of Latin America Pharmacogenomics revenue, By Application, 2016-2025 (USD Million)
        • 8.5.6.3. Rest of Latin America Pharmacogenomics revenue, By End User, 2016-2025 (USD Million)
    • 8.6. The Middle East and Africa
      • 8.6.1. The Middle East and Africa Pharmacogenomics, 2016-2025 (USD Million)
      • 8.6.2. The Middle East and Africa Pharmacogenomics revenue, By Technology,2016-2025 (USD Million)
      • 8.6.3. The Middle East and Africa Pharmacogenomics revenue, By Application, 2016-2025 (USD Million)
      • 8.6.4. The Middle East and Africa Pharmacogenomics revenue, By End User, 2016-2025 (USD Million)
  • Chapter 9. Company Profiles
    • 9.1. Dynamic DNA Laboratories
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Technology Portfolio
      • 9.1.4. Business Strategy
      • 9.1.5. Recent Developments
    • 9.2. Abbott Laboratories
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Technology Portfolio
      • 9.2.4. Business Strategy
      • 9.2.5. Recent Developments
    • 9.3. Empire Genomics, LLC
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Technology Portfolio
      • 9.3.4. Business Strategy
      • 9.3.5. Recent Developments
    • 9.4. Illumina, Inc.
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Technology Portfolio
      • 9.4.4. Business Strategy
      • 9.4.5. Recent Developments
    • 9.5. F. Hoffmann-La Roche Ltd.
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Technology Portfolio
      • 9.5.4. Business Strategy
      • 9.5.5. Recent Development
    • 9.6. Myriad Genetics Inc.
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Technology Portfolio
      • 9.6.4. Business Strategy
      • 9.6.5. Recent Development
    • 9.7. OneOme LLC
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Technology Portfolio
      • 9.7.4. Business Strategy
      • 9.7.5. Recent Development
    • 9.8. Thermo Fisher Scientific, Inc.
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Technology Portfolio
      • 9.8.4. Business Strategy
      • 9.8.5. Recent Development
    • 9.9. OPKO Health, Inc.
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Technology Portfolio
      • 9.9.4. Business Strategy
      • 9.9.5. Recent Development

List of Figures

1. Market research process
2. Market research methodology
3. Global Pharmacogenomics, 2016–2025 (USD Million)
4. Porter’s Five Forces Analysis
5. Global Pharmacogenomics attractiveness, By Technology type
6. Global Pharmacogenomics attractiveness, By Application
7. Global Pharmacogenomics attractiveness, By End User
8. Global Pharmacogenomics market share, By Technology, 2018 and 2025
9. Global Pharmacogenomics by Microarray, 2016–2025 (USD Million)
10. Global Pharmacogenomics by Polymerase Chain Reaction,2016–2025 (USD Million)
11. Global Pharmacogenomics by Sequencing,2016–2025 (USD Million)
12. Global Pharmacogenomics by Electrophoresis,2016–2025 (USD Million)
13. Global Pharmacogenomics by Mass Spectrometry,2016–2025 (USD Million)
14. Global Pharmacogenomics by Others,2016–2025 (USD Million)
15. Global Pharmacogenomics share, By Application, 2018 and 2025
16. Global Pharmacogenomics By Infectious Diseases, 2016–2025 (USD Million)
17. Global Pharmacogenomics By Oncology, 2016–2025 (USD Million)
18. Global Pharmacogenomics By Neurological Diseases, 2016–2025 (USD Million)
19. Global Pharmacogenomics By Cardiovascular Diseases, 2016–2025 (USD Million)
20. Global Pharmacogenomics By Infectious Disease, 2016–2025 (USD Million)
21. Global Pharmacogenomics By Pain Management, 2016–2025 (USD Million)
22. Global Pharmacogenomics By Psychiatry, 2016–2025 (USD Million)
23. Global Pharmacogenomics By Others, 2016–2025 (USD Million)
24. Global Pharmacogenomics share, By End User, 2018 and 2025
25. Global Pharmacogenomics by Research Institutions, 2016–2025 (USD Million)
26. Global Pharmacogenomics by Hospitals and Clinics, 2016–2025 (USD Million)
27. Global Pharmacogenomics by Academic Institutes, 2016–2025 (USD Million)
28. Global Pharmacogenomics share, by Region, 2018and 2025
29. North America Pharmacogenomics, 2016–2025 (USD Million)
30. Europe Pharmacogenomics, 2016–2025 (USD Million)
31. Asia Pacific Pharmacogenomics, 2016–2025 (USD Million)
32. Latin America Pharmacogenomics, 2016–2025 (USD Million)
33. The Middle East and Africa Pharmacogenomics, 2016–2025 (USD Million)


List of Tables

1. Global Pharmacogenomics: snapshot
2. Drivers of the Pharmacogenomics: impact analysis
3. Restraints of the Pharmacogenomics: impact analysis
4. North America Pharmacogenomics revenue, By Technology,2016–2025 (USD Million)
5. North America Pharmacogenomics revenue, By Application, 2016–2025 (USD Million)
6. North America Pharmacogenomics revenue, By End User, 2016–2025 (USD Million)
7. The U.S. Pharmacogenomics revenue, By Technology,2016–2025 (USD Million)
8. The U.S. Pharmacogenomics revenue, By Application, 2016–2025 (USD Million)
9. The U.S. Pharmacogenomics revenue, By End User, 2016–2025 (USD Million)
10. Rest of North America Pharmacogenomics revenue, By Technology,2016–2025 (USD Million)
11. Rest of North America Pharmacogenomics revenue, By Application, 2016–2025 (USD Million)
12. Rest of North America Pharmacogenomics revenue, By End User, 2016–2025 (USD Million)
13. Europe Pharmacogenomics revenue, By Technology,2016–2025 (USD Million)
14. Europe Pharmacogenomics revenue, By Application, 2016–2025 (USD Million)
15. Europe Pharmacogenomics revenue, By End User, 2016–2025 (USD Million)
16. U.K. Pharmacogenomics revenue, By Technology,2016–2025 (USD Million)
17. U.K. Pharmacogenomics revenue, By Application, 2016–2025 (USD Million)
18. U.K. Pharmacogenomics revenue, By End User, 2016–2025 (USD Million)
19. France Pharmacogenomics revenue, By Technology,2016–2025 (USD Million)
20. France Pharmacogenomics revenue, By Application, 2016–2025 (USD Million)
21. France Pharmacogenomics revenue, By End User, 2016–2025 (USD Million)
22. Germany Pharmacogenomics revenue, By Technology,2016–2025 (USD Million)
23. Germany Pharmacogenomics revenue, By Application, 2016–2025 (USD Million)
24. Germany Pharmacogenomics revenue, By End User, 2016–2025 (USD Million)
25. Rest of Europe Pharmacogenomics revenue, By Technology,2016–2025 (USD Million)
26. Rest of Europe Pharmacogenomics revenue, By Application, 2016–2025 (USD Million)
27. Rest of Europe Pharmacogenomics revenue, By End User, 2016–2025 (USD Million)
28. Asia Pacific Pharmacogenomics revenue, By Technology,2016–2025 (USD Million)
29. Asia Pacific Pharmacogenomics revenue, By Application, 2016–2025 (USD Million)
30. Asia Pacific Pharmacogenomics revenue, By End User, 2016–2025 (USD Million)
31. China Pharmacogenomics revenue, By Technology,2016–2025 (USD Million)
32. China Pharmacogenomics revenue, By Application, 2016–2025 (USD Million)
33. China Pharmacogenomics revenue, By End User, 2016–2025 (USD Million)
34. Japan Pharmacogenomics revenue, By Technology,2016–2025 (USD Million)
35. Japan Pharmacogenomics revenue, By Application, 2016–2025 (USD Million)
36. Japan Pharmacogenomics revenue, By End User, 2016–2025 (USD Million)
37. India Pharmacogenomics revenue, By Technology,2016–2025 (USD Million)
38. India Pharmacogenomics revenue, By Application, 2016–2025 (USD Million)
39. India Pharmacogenomics revenue, By End User, 2016–2025 (USD Million)
40. Rest of Asia Pacific Pharmacogenomics revenue, By Technology,2016–2025 (USD Million)
41. Rest of Asia Pacific Pharmacogenomics revenue, By Application, 2016–2025 (USD Million)
42. Rest of Asia Pacific Pharmacogenomics revenue, By End User, 2016–2025 (USD Million)
43. Latin America Pharmacogenomics revenue, By Technology,2016–2025 (USD Million)
44. Latin America Pharmacogenomics revenue, By Application, 2016–2025 (USD Million)
45. Latin America Pharmacogenomics revenue, By End User, 2016–2025 (USD Million)
46. Brazil Pharmacogenomics revenue, By Technology,2016–2025 (USD Million)
47. Brazil Pharmacogenomics revenue, By Application, 2016–2025 (USD Million)
48. Brazil Pharmacogenomics revenue, By End User, 2016–2025 (USD Million)
49. Rest of Latin America Pharmacogenomics revenue, By Technology,2016–2025 (USD Million)
50. Rest of Latin America Pharmacogenomics revenue, By Application, 2016–2025 (USD Million)
51. Rest of Latin America Pharmacogenomics revenue, By End User, 2016–2025 (USD Million)
52. The Middle East and Africa Pharmacogenomics revenue, By Technology,2016–2025 (USD Million)
53. The Middle East and Africa Pharmacogenomics revenue, By Application, 2016–2025 (USD Million)
54. The Middle East and Africa Pharmacogenomics revenue, By End User, 2016–2025 (USD Million)
 

Methodology

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed